Market Ignores AbbVie’s Impressive Sales Due To Reliance On Humira | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 25 July, 2014 by The TZ Newswire Staff

Market Ignores AbbVie’s Impressive Sales Due To Reliance On Humira

By The Value Investor:

AbbVie (NYSE:ABBV) released a relatively strong set of second quarter results on Friday, yet shares lost some ground during the session.

See also
- Next Article NQ Mobile Rises 93% In One Week From Its 52-Week Low
- Previous Article Market Outlook By Market-Making Pros, Aggregating 2500+ Stocks And ETFs
Editorial Calender

July 2014

M T W T F S S

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

« Jun Aug »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar